OR WAIT null SECS
July 04, 2024
The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
July 03, 2024
The company is referring to its search for innovative approaches as crowdsourcing and will award at least one cash prize.
July 01, 2024
EMA has accepted GSK’s application seeking treatment with Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.
June 28, 2024
The typical cycle of ceasing and then reinitiating fremanezumab treatments may actually result in increased monthly migraine days, the study said.
The Celsius Therapeutics acquisition will add CEL383, a potential first-in-class anti-TREM1 antibody for IBD, to AbbVie’s portfolio.
June 27, 2024
With the Proteologix acquisition, Johnson & Johnson gains two bispecific antibody early phase assets for immune-mediated diseases.
June 26, 2024
Novo Nordisk plans to invest $4.1 billion in a second fill/finish manufacturing facility in Clayton, N.C., boosting its current 2024 investments into production to $6.8 billion.
Fruzaqla was previously approved for use in patients with metastatic colorectal cancer in the US in November 2023.
June 25, 2024
FDA has granted expanded approval to Sarepta Therapeutics for Elevidys to treat DMD in non-ambulatory patients, in addition to ambulatory patients.
Immunology company argenx gets its third FDA-approved indication for VYVGART Hytrulo for treating chronic inflammatory demyelinating polyneuropathy.